Urate-lowering therapy for the management of gout: Summary of 2 cochrane reviews

Journal of Rheumatology

Volumn 41, Issue SUPPL. 92, 2014, Pages 33-41

  Kydd, Alison S ^a   Seth, Rakhi ^b   Buchbinder, Rachelle ^c   Falzon, Louise ^d   Edwards, Christopher J ^b   Van Der Heijde, Désirée M ^e   Bombardier, Claire ^f,g,h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d Department of Medicine   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Allopurinol; Febuxostat; Gout; Pegloticase; Treatment; Uricosuric agents

Indexed keywords

URIC ACID; URICOSURIC AGENT;

BLOOD; GOUT; HUMAN; TREATMENT OUTCOME;

GOUT; HUMANS; TREATMENT OUTCOME; URIC ACID; URICOSURIC AGENTS;

EID: 84906847534     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140460     Document Type: Review

References (57)

1. Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014;73:328-35.
2. Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout [Protocol]. Cochrane Database Syst Rev 2013;4:4.
3. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout [Protocol]. Cochrane Database Syst Rev 2013;4:4.
4. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014;(submitted).
5. Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev 2013;4:CD006077.
6. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org.
7. Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al. Patient-reported outcomes in chronic gout: A report from OMERACT 10. J Rheumatol 2011;38:1452-7.
8. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
9. Higgins JP, Altman DG, Sterne JAC, editors. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37. (Pubitemid 46768164)
11. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Internet. Accessed May 29, 2014.] Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
12. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
13. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
14. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: A controlled study. Ann Rheum Dis 1982;41:59-65. (Pubitemid 12136653)
15. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55. (Pubitemid 29217861)
16. Reinders MK, Haagsma C, Jansen TLTA, van Roon EN, Delsing J, van de Laar MAFJ, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7.
17. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
18. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989;16:1246-8. (Pubitemid 19260116)
19. Rodnan GP, Robin JA, Tolchin SF, Elion GB. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA 1975;231:1143-7.
20. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966;25 Suppl:623-6.
21. Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, Gonzalez-Gay MA. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res 2010;62:1299-305.
22. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
23. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
24. Foong HBB. Allopurinol and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Royal Coll Phys Edinburgh 2009;39:144-5.
25. Arellano F, Sacristan JA, Saint-Pierre J. Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 1993;27:337-43. (Pubitemid 23086961)
26. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50. (Pubitemid 44168841)
27. Fraunfelder FT, Hanna C, Dreis MW, Cosgrove KW Jr. Cataracts associated with allopurinol therapy. Am J Ophthalmol 1982;94:137-40. (Pubitemid 12038544)
28. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;l76:47-56.
29. Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J 1979;72:1361-8.
30. Liu CS, Brown NA, Leonard TJ, Bull PW, Scott JT. The prevalence and morphology of cataract in patients on allopurinol treatment. Eye 1988;2 Pt 6:600-6. (Pubitemid 19141539)
31. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7. (Pubitemid 17015410)
32. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3. (Pubitemid 32885676)
33. Lee HY, Ariyasinghe JTN, Thirumoorthy T. Allopurinol hypersensitivity syndrome: A preventable severe cutaneous adverse reaction? Singapore Med J 2008;49:384-7. (Pubitemid 351716706)
34. Reinders MK, van Roon EN, Houtman PM, Brouwers JRBJ, Jansen TLTA. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007;26:1459-65. (Pubitemid 47201684)
35. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23. (Pubitemid 40372228)
36. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009;48:188-94.
37. Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: Serum urate response in uric acid overproducers and underexcretors. J Rheumatol 2011;38:1385-9.
38. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: Long-term treatment effects of febuxostat. J Clin Rheumatol 2011;17:7-13.
39. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011;38:1957-9.
40. Reinders MK, van Roon EN, Jansen TLTA, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
41. Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 2011;306:711-20.
42. Sundy JS, Becker MA, Baraf HSB, Barkhuizen A, Moreland LW, Huang W, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008;58:2882-91.
43. Singh JA, Yang S, Strand V, Simon L, Forsythe A, Hamburger S, et al. Validation of pain and patient global scales in chronic gout: Data from two randomised controlled trials. Ann Rheum Dis 2011;70:1277-81.
44. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006;8:R12.
45. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. [Erratum in: Arthritis Rheum 2007;56:1370]. Arthritis Rheum 2007;56:1021-8. (Pubitemid 46399452)
46. Kavanaugh A, Ruderman E. Pegloticase and concomitant urate lowering therapies. [Internet. updated 2012; accessed May 29, 2014.] Available from: http://www.rheumatology.org/publications/hotline/2012-01-18-pegloticase.asp
47. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: A NICE single technology appraisal. Pharmacoeconomics 2011;29:133-40.
48. Febuxostat for the management of hyperuricaemia in people with gout: National Institute for Health and Clinical Excellence; December 2008 (Review date August 2011). Report No.: NICE technology appraisal guidance 164. [Internet. Accessed May 29, 2014.] Available from: http://www.nice.org.uk/ nicemedia/pdf/TA164Guidance.pdf
49. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-14.
50. Group NGD. National Institute for Health and Clinical Excellence (NICE) Guideline Manual. National Institute for Health Care Excellence; 2012 [Internet. Updated 2012; accessed May 29, 2014.] Available from: http://publications.nice. org.uk/the-guidelines-manual-pmg6.
51. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.
52. Hamburger M, Baraf HSB, Adamson TC Jr, Basile J, Bass L, Cole B, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Physician Sportsmedicine 2011;39:98-123.
53. Khanna P, Singh MK, Bae S, FitzGerald JD, Prakash S, Kaldas M, et al. Oral urate lowering therapies in chronic gout: A systematic review and meta-analysis [abstract]. Arthritis Rheum 2011;63 Suppl:S405.
54. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
55. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5. (Pubitemid 36608946)
56. Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011;38:904-10.
57. Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 2008;47:111-8.